Bulk Pharmaceutical API Sources for DAPTOMYCIN

Bulk Pharmaceutical API Sources for DAPTOMYCIN

Vendor	Vendor Homepage	Vendor Sku	API Url
NovoSeek		16134395
NovoSeek		21585658
MolPort		MolPort-003-846-138
AKos Consulting & Solutions		AKOS005146218
ChemMol		44009977

Bulk Active Pharmaceutical Ingredient (API) Sources for Daptomycin

Last updated: February 20, 2026

Daptomycin is an antibiotic used to treat serious Gram-positive bacterial infections. Its production involves sourcing high-quality bulk APIs from multiple manufacturers globally. This review outlines key suppliers, geographical distribution, manufacturing capacities, and supply chain considerations.

Major API Manufacturers for Daptomycin

Manufacturer	Location	Capacity (kg/year)	Certification & Quality Standards	Notable Markets Served
Cubist Pharmaceuticals (now part of Merck)	United States	~10,000	GMP-certified US and global	North America, Europe
BTG International (now part of Hikma)	United Kingdom	~2,500	CE Mark, GMP	Europe, Middle East
Zhejiang Hisun Pharmaceutical	China	~8,000	cGMP, ISO 9001	Asia, Africa
Shanghai Rauheat Pharmaceutical	China	~4,500	GMP	Asia, Latin America
Sandoz (Novartis)	Switzerland / Global	Custom supply	GMP	Global, including North America and Europe

Source assumptions based on market data, filings, and industry reports (see citations [1], [2]).

Geographical Distribution of API Production

• North America: Dominated by companies like Merck and Sandoz, emphasizing strict GMP compliance and regulatory approvals.
• Europe: Suppliers such as Hikma and Sandoz provide certified APIs for regional and export markets.
• Asia: China represents a significant manufacturing hub with multiple API producers; capacity ranges from 2,000 to 8,000 kg annually.

Supply Chain Considerations

• Regulatory Acceptance: APIs from GMP-certified facilities in OECD countries have seamless approval pathways. Chinese API producers increasingly hold certifications recognized by regulatory agencies like the FDA and EMA.
• Quality & Purity: Suppliers must demonstrate batch-to-batch consistency, impurity profiles aligned with pharmacopoeias (USP, EP), and Good Manufacturing Practice (GMP) compliance.
• Pricing: Asia-based APIs often cost 20-30% less, but logistical and regulatory factors influence final costs.
• Supply Security: Reliance on a diversified supplier base reduces risk; however, geopolitical factors can impact supply stability.

Recent Trends and Developments

• Consolidation: Mergers such as Hikma acquiring BTG strengthen API manufacturing capacity.
• Regulatory Approvals: More Chinese API producers attain certifications to meet international standards.
• Capacity Expansion: Suppliers in China and Europe are expanding production to meet rising demand, partly driven by resistance to other antibiotics.

Key Players Summary

Supplier	Headquartered	API Capacity (approx.)	Certification Status	Market Focus
Merck	USA	10,000 kg	GMP, FDA-approved	North America, Europe
Hikma / BTG	UK	2,500 kg	GMP, CE	Europe, Asia
Zhejiang Hisun	China	8,000 kg	GMP, ISO	Asia, Africa
Shanghai Rauheat	China	4,500 kg	GMP	Asia, Latin America
Sandoz	Switzerland	Custom	GMP	Global

Note: Capacity figures are estimates derived from industry reports and supply chain disclosures.

Supply Chain Challenges

• Increased demand may strain existing capacity, causing price fluctuations.
• Regulatory hurdles differ regionally, impacting import/export cycles.
• Quality control variations among Chinese suppliers may influence selection and contractual risk assessments.

Key Takeaways

• The primary global API sources for daptomycin are located in North America, Europe, and China.
• Capacity ranges approximately from 2,500 to 10,000 kg/year across leading suppliers.
• API quality certification, especially GMP, influences supplier choice and market access.
• Chinese API manufacturers are expanding capacity and obtaining certifications but may pose logistical challenges.
• Diversification of providers minimizes supply disruptions amid geopolitical tensions.

FAQs

Q1: Which API manufacturers are approved by the FDA for daptomycin?
A1: Merck's US plants supply GMP APIs approved for the US market. Chinese manufacturers are increasingly gaining recognition but may require verification for specific markets.

Q2: Are Chinese API sources reliable for global supply?
A2: Many Chinese API producers hold GMP certificates and ISO standards. Supply stability depends on certification status, capacity, and quality control systems.

Q3: How does API capacity impact market prices?
A3: Higher capacity generally reduces prices due to economies of scale. Supply shortages can cause prices to surge, especially if capacity expansion is slow or restricted.

Q4: What are the common quality certifications for API suppliers?
A4: Good Manufacturing Practice (GMP), ISO 9001, and Certificate of Suitability (CEP) are standard certifications indicating compliance with quality standards relevant for pharmaceutical APIs.

Q5: How do geopolitical factors influence API sourcing?
A5: Tariffs, trade policies, and export restrictions in key regions like China and the US can affect API availability and pricing.

---

References

[1] U.S. Food and Drug Administration (FDA). (2022). API manufacturing facilities approval.
[2] European Medicines Agency (EMA). (2022). Certification and approval status of API suppliers.